Compare Stocks: BNR, EDIT, PBYI, and KMDA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNR Burning Rock Biotech	$15.08 +2.4%	$10.22	$6.79 ▼ $41.72	$154.91M	1.38	51,936 shs	9,972 shs
EDIT Editas Medicine	$2.83 -0.2%	$2.89	$1.66 ▼ $4.54	$433.86M	2.09	2.19 million shs	1,255 shs
KMDA Kamada	$8.68 -0.7%	$7.73	$6.50 ▼ $9.35	$497.99M	0.88	78,520 shs	475 shs
PBYI Puma Biotechnology	$9.66 +0.7%	$8.80	$4.47 ▼ $9.75	$498.44M	1.24	337,714 shs	632 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNR Burning Rock Biotech	+3.51%	+26.98%	+50.61%	+94.33%	+71.96%
EDIT Editas Medicine	+4.81%	+3.28%	-9.00%	+2.54%	0.00%
KMDA Kamada	-1.24%	+5.17%	+6.07%	+22.58%	+26.48%
PBYI Puma Biotechnology	-0.10%	+4.92%	+3.79%	+19.28%	+116.97%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNR Burning Rock Biotech	$15.08 +2.4%	$10.22	$6.79 ▼ $41.72	$154.91M	1.38	51,936 shs	9,972 shs
EDIT Editas Medicine	$2.83 -0.2%	$2.89	$1.66 ▼ $4.54	$433.86M	2.09	2.19 million shs	1,255 shs
KMDA Kamada	$8.68 -0.7%	$7.73	$6.50 ▼ $9.35	$497.99M	0.88	78,520 shs	475 shs
PBYI Puma Biotechnology	$9.66 +0.7%	$8.80	$4.47 ▼ $9.75	$498.44M	1.24	337,714 shs	632 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNR Burning Rock Biotech	+3.51%	+26.98%	+50.61%	+94.33%	+71.96%
EDIT Editas Medicine	+4.81%	+3.28%	-9.00%	+2.54%	0.00%
KMDA Kamada	-1.24%	+5.17%	+6.07%	+22.58%	+26.48%
PBYI Puma Biotechnology	-0.10%	+4.92%	+3.79%	+19.28%	+116.97%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BNR Burning Rock Biotech	1.00	Sell	N/A	N/A
EDIT Editas Medicine	2.60	Moderate Buy	$6.00	112.39% Upside
KMDA Kamada	3.00	Buy	$13.50	55.53% Upside
PBYI Puma Biotechnology	2.00	Hold	$6.00	-37.86% Downside

Current Analyst Ratings Breakdown

Latest BNR, EDIT, PBYI, and KMDA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/18/2026	KMDA Kamada	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$15.00
9/10/2026	BNR Burning Rock Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/27/2026	BNR Burning Rock Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/21/2026	PBYI Puma Biotechnology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C) ➝ Hold (C+)
8/18/2026	EDIT Editas Medicine	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$6.00
8/13/2026	BNR Burning Rock Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/11/2026	EDIT Editas Medicine	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/7/2026	PBYI Puma Biotechnology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)
8/7/2026	PBYI Puma Biotechnology	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Hold	$5.00 ➝ $6.00
7/31/2026	BNR Burning Rock Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/21/2026	KMDA Kamada	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy

(Data available from 9/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BNR Burning Rock Biotech	$77.16M	2.06	N/A	N/A	$7.28 per share	2.07
EDIT Editas Medicine	$40.52M	10.71	N/A	N/A	$0.28 per share	10.09
KMDA Kamada	$191.85M	2.60	$0.60 per share	14.49	$4.68 per share	1.85
PBYI Puma Biotechnology	$228.40M	2.18	$0.84 per share	11.51	$2.59 per share	3.73

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BNR Burning Rock Biotech	-$7.92M	-$0.87	N/A	N/A	N/A	-13.60%	-12.98%	-8.59%	11/17/2026 (Estimated)
EDIT Editas Medicine	-$160.06M	-$0.75	N/A	N/A	N/A	-157.32%	-196.63%	-38.17%	11/9/2026 (Estimated)
KMDA Kamada	$20.20M	$0.38	22.79	14.47	0.72	11.60%	8.37%	5.85%	11/9/2026 (Estimated)
PBYI Puma Biotechnology	$31.11M	$0.52	18.57	68.96	N/A	11.50%	20.76%	13.22%	11/5/2026 (Estimated)

Latest BNR, EDIT, PBYI, and KMDA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/10/2026	Q2 2026	BNR Burning Rock Biotech	-$2.2883	-$0.20	+$2.0883	-$0.25	$19.21 million	$19.84 million
8/12/2026	Q2 2026	KMDA Kamada	$0.1125	$0.16	+$0.0475	$0.16	$50.84 million	$54.92 million
8/6/2026	Q2 2026	PBYI Puma Biotechnology	$0.04	$0.19	+$0.15	$0.16	$53.00 million	$56.50 million
8/5/2026	Q2 2026	EDIT Editas Medicine	-$0.2705	-$0.15	+$0.1205	-$0.15	$2.85 million	$11.89 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BNR Burning Rock Biotech	N/A	N/A	N/A	N/A	N/A
EDIT Editas Medicine	N/A	N/A	N/A	N/A	N/A
KMDA Kamada	$0.12	1.38%	N/A	31.58%	N/A
PBYI Puma Biotechnology	N/A	N/A	N/A	N/A	N/A

Latest BNR, EDIT, PBYI, and KMDA Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
8/17/2026	KMDA Kamada	annual	$0.17	2.06%	8/27/2026	8/27/2026	9/17/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BNR Burning Rock Biotech	N/A	3.05	2.90
EDIT Editas Medicine	N/A	3.19	3.19
KMDA Kamada	N/A	4.06	2.29
PBYI Puma Biotechnology	N/A	2.91	2.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BNR Burning Rock Biotech	30.03%
EDIT Editas Medicine	71.90%
KMDA Kamada	20.38%
PBYI Puma Biotechnology	61.29%

Insider Ownership

Company	Insider Ownership
BNR Burning Rock Biotech	30.30%
EDIT Editas Medicine	3.10%
KMDA Kamada	36.10%
PBYI Puma Biotechnology	22.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BNR Burning Rock Biotech	667	10.52 million	7.33 million	Not Optionable
EDIT Editas Medicine	87	153.58 million	148.82 million	Optionable
KMDA Kamada	462	57.51 million	36.75 million	Optionable
PBYI Puma Biotechnology	179	51.62 million	40.16 million	Optionable

BNR, EDIT, PBYI, and KMDA Headlines

Recent News About These Companies

Puma Biotechnology Initiates ALISCA(R)-Lung2, a Phase II Trial of Alisertib in Combination with Paclitaxel for the Treatment of Patients with Advanced Small Cell Lung Cancer

September 18, 2026 | marketscreener.comM

Puma Biotechnology Advances Alisertib Combo Trial in Small Cell Lung Cancer

September 18, 2026 | tipranks.com

PBYI's Alisertib Combo Phase II Study in Small Cell Lung Cancer Begins

September 18, 2026 | zacks.com

Alessandra Cesano Sells 62,150 Shares of Puma Biotechnology (NASDAQ:PBYI) Stock

September 18, 2026 | americanbankingnews.com

Puma Biotechnology Initiates ALISCA®-Lung2, a Phase II Trial of Alisertib in Combination with Paclitaxel for the Treatment of Patients with Advanced Small Cell Lung Cancer

September 17, 2026 | businesswire.com

Insider Selling: Puma Biotechnology (NASDAQ:PBYI) Director Sells $45,500.00 in Stock

September 17, 2026 | insidertrades.com

Troy Edward Wilson Sells 5,000 Shares of Puma Biotechnology (NASDAQ:PBYI) Stock

September 16, 2026 | marketbeat.com

Insider Selling: Puma Biotechnology (NASDAQ:PBYI) Director Sells $566,808.00 in Stock

September 16, 2026 | marketbeat.com

Wellington Management Group LLP Invests $1.02 Million in Puma Biotechnology, Inc. $PBYI

September 12, 2026 | marketbeat.com

Puma Biotechnology to Present at H.C. Wainwright’s 28th Annual Global Investment Conference

September 9, 2026 | finance.yahoo.com

Puma Biotechnology to Present at H.C. Wainwright's 28th Annual Global Investment Conference

September 9, 2026 | businesswire.com

Bank of New York Mellon Corp Takes $2.93 Million Position in Puma Biotechnology, Inc. $PBYI

September 7, 2026 | marketbeat.com

220,316 Shares in Puma Biotechnology, Inc. $PBYI Purchased by Empowered Funds LLC

September 4, 2026 | marketbeat.com

Zacks Research Has Positive Outlook of PBYI FY2026 Earnings

September 3, 2026 | marketbeat.com

Puma Biotechnology (NASDAQ:PBYI) Sets New 12-Month High - Still a Buy?

September 2, 2026 | marketbeat.com

Q3 EPS Forecast for Puma Biotechnology Lowered by Analyst

September 2, 2026 | marketbeat.com

3,804,736 Shares in Puma Biotechnology, Inc. $PBYI Bought by BlackRock Inc.

September 2, 2026 | marketbeat.com

Connor Clark & Lunn Investment Management Ltd. Acquires New Holdings in Puma Biotechnology, Inc. $PBYI

August 28, 2026 | marketbeat.com

Globeflex Capital L P Invests $3.10 Million in Puma Biotechnology, Inc. $PBYI

August 24, 2026 | marketbeat.com

Is Puma Biotechnology (PBYI) a Great Value Stock Right Now?

August 12, 2026 | zacks.com

Puma Biotechnology, Inc. 2026 Q2 - Results - Earnings Call Presentation

August 10, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

BNR, EDIT, PBYI, and KMDA Company Descriptions

Burning Rock Biotech NASDAQ:BNR

$15.08 +0.35 (+2.37%)

As of 09:35 AM Eastern

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; and OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC. In addition, the company provides ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and brPROPHET, a pre-operative ctDNA detection and post-operative MRD calling for relapsed patients. Further, it has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, and IMPACT Therapeutics and Merck KGaA. Additionally, the company offers OncoMaster, an automatic NGS data analysis and report interpretation machine for in-hospital model. Burning Rock Biotech Limited was incorporated in 2014 and is headquartered in Guangzhou, China.

Editas Medicine NASDAQ:EDIT

$2.82 -0.01 (-0.18%)

As of 09:48 AM Eastern

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Kamada NASDAQ:KMDA

$8.68 -0.06 (-0.69%)

As of 09:45 AM Eastern

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

Puma Biotechnology NASDAQ:PBYI

$9.65 +0.07 (+0.68%)

As of 09:47 AM Eastern

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BNR, EDIT, PBYI, and KMDA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BNR, EDIT, PBYI, and KMDA Earnings

Compare Dividends

Latest BNR, EDIT, PBYI, and KMDA Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BNR, EDIT, PBYI, and KMDA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

BNR, EDIT, PBYI, and KMDA Company Descriptions

Burning Rock Biotech NASDAQ:BNR

Editas Medicine NASDAQ:EDIT

Kamada NASDAQ:KMDA

Puma Biotechnology NASDAQ:PBYI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools